WASHINGTON, D.C. — Children with a life-threatening immune disorder now have a new treatment option following federal approval of the first gene therapy designed to correct the underlying cause of the disease.
What This Means for You
- Children with a rare immune disorder may have a new treatment option when no donor match is available
- The therapy targets the genetic cause of the disease using the patient’s own cells
- Approval is conditional, with further studies required to confirm long-term benefits
The U.S. Food and Drug Administration approved Kresladi, a one-time gene therapy for pediatric patients with severe Leukocyte Adhesion Deficiency Type I, a rare inherited condition that prevents white blood cells from properly fighting infections.
The therapy is intended for children who do not have a suitable donor for a stem cell transplant, which is currently the standard treatment but carries significant risks.
How the Therapy Works
Kresladi uses a patient’s own blood stem cells, which are modified in a laboratory to correct a defective gene known as ITGB2.
After the cells are reintroduced into the body, they are designed to restore the function of white blood cells by enabling key proteins needed to fight infections.
This approach targets the root cause of the disease rather than treating symptoms.
A High-Risk Condition
Severe Leukocyte Adhesion Deficiency Type I is a rare genetic disorder that leads to repeated, serious bacterial and fungal infections, often beginning in early childhood.
Without effective treatment, the condition carries a high risk of illness and death within the first decade of life.
Clinical Evidence and Approval Pathway
The FDA granted accelerated approval based on evidence that the therapy improved biological markers tied to immune function — specifically increased expression of proteins that help white blood cells respond to infections.
Accelerated approval allows drugs to reach patients sooner when early data suggests benefit, while requiring additional studies to confirm long-term effectiveness.
The supporting clinical trial showed sustained improvements in these immune markers through at least two years after treatment.
Safety and Side Effects
Common side effects observed in the study included anemia, low blood cell counts, infections, fever, nausea, and elevated liver enzymes.
Patients may also experience complications related to the treatment process, which involves modifying and reinfusing their own cells.
Next Steps
The therapy’s manufacturer, Rocket Pharmaceuticals, is required to conduct further studies to confirm clinical benefits.
Continued approval of the treatment will depend on the results of those follow-up trials.
The FDA also granted the therapy multiple expedited designations, including orphan drug and rare pediatric disease status, to support development for this small patient population.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.